Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 161 points (1.0%) at 15,537 as of Monday, Sept. 16, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 2,425 issues advancing vs. 535 declining with 80 unchanged. The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 1.9%, Valeant Pharmaceuticals International ( VRX), up 1.8%, Novo Nordisk A/S ( NVO), up 1.6%, AstraZeneca ( AZN), up 1.6% and Eli Lilly and Company ( LLY), up 0.9%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.70 (-0.9%) to $75.50 on heavy volume. Thus far, 1.4 million shares of Novartis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $75.28-$76.01 after having opened the day at $76.00 as compared to the previous trading day's close of $76.20. Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $186.4 billion and is part of the health care sector. Shares are up 20.3% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.